Felistia, Yuli
Wen, Patrick Y.
Article History
Accepted: 16 August 2023
First Online: 9 October 2023
Declarations
:
: Yuli Felistia declares no potential conflicts of interest. Patrick Y. Wen has received research support from Astra Zeneca, Black Diamond, Bristol Meyers Squibb, Celgene, Chimerix, Eli Lily, Erasca, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Servier, Vascular Biogenics, and VBI Vaccines (Advisory Board/Consultant: Astra Zeneca, Black Diamond, Celularity, Chimerix, Day One Bio, Genenta, Glaxo Smith Kline, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, VBI Vaccines).
: This article does not contain any studies with human or animal subjects performed by any of the authors.